应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。
关闭
02493 迈威生物-B
已收盘 09-22 16:08:11
21.380
+0.180
+0.85%
最高
21.880
最低
21.020
成交量
21.64万
今开
21.740
昨收
21.200
日振幅
4.06%
总市值
95.57亿
流通市值
10.08亿
总股本
4.47亿
成交额
465.18万
换手率
0.46%
流通股本
4,713万
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）
资讯
新帖
简况
9月21日迈威生物涨5.41%，中航优选领航混合发起A基金重仓该股
证券之星 · 09-21 16:40
9月21日迈威生物涨5.41%，中航优选领航混合发起A基金重仓该股
迈威生物涨5.41%，中邮证券一周前给出“买入”评级
证券之星 · 09-21 16:39
迈威生物涨5.41%，中邮证券一周前给出“买入”评级
迈威生物：基于上半年的增长，对今年的药品销售收入预期较为乐观
同花顺 · 09-20 13:22
迈威生物：基于上半年的增长，对今年的药品销售收入预期较为乐观
迈威生物：公司TCE平台的第一款分子LILRB4/CD3中美临床均已获批
同花顺 · 09-20 13:19
迈威生物：公司TCE平台的第一款分子LILRB4/CD3中美临床均已获批
迈威生物：2MW7141去年完成了海外授权，目前处于临床前阶段
同花顺 · 09-20 13:16
迈威生物：2MW7141去年完成了海外授权，目前处于临床前阶段
迈威生物：B7-H3 ADC的适应症主要面向鳞状非小细胞肺癌，下半年正式启动
同花顺 · 09-20 13:08
迈威生物：B7-H3 ADC的适应症主要面向鳞状非小细胞肺癌，下半年正式启动
迈威生物：ST2单抗目前开展的是COPD的IIb期临床，期中分析有望在今年年内完成
同花顺 · 09-20 12:03
迈威生物：ST2单抗目前开展的是COPD的IIb期临床，期中分析有望在今年年内完成
迈威生物：Nectin-4 ADC是公司目前有望最先获得商业化验证的原创新药
同花顺 · 09-20 11:54
迈威生物：Nectin-4 ADC是公司目前有望最先获得商业化验证的原创新药
迈威生物-B(02493)三项议案高票获批 第四次临时股东会完成
公告速递 · 09-17
迈威生物-B(02493)三项议案高票获批 第四次临时股东会完成
迈威生物-B公布2026年第四次临时股东会表决结果及章程修订进展
公告速递 · 09-17
迈威生物-B公布2026年第四次临时股东会表决结果及章程修订进展
迈威生物：2026年第四次临时股东会决议公告
同花顺 · 09-17
迈威生物：2026年第四次临时股东会决议公告
9月14日迈威生物涨7.19%，中航优选领航混合发起A基金重仓该股
证券之星 · 09-14
9月14日迈威生物涨7.19%，中航优选领航混合发起A基金重仓该股
迈威生物涨7.19%，中邮证券四日前给出“买入”评级
证券之星 · 09-14
迈威生物涨7.19%，中邮证券四日前给出“买入”评级
9月11日迈威生物跌6.02%，中航优选领航混合发起A基金重仓该股
证券之星 · 09-11
9月11日迈威生物跌6.02%，中航优选领航混合发起A基金重仓该股
ERS年会壁报发布临床结果 迈威生物9MW1911价值几何？
新浪证券 · 09-11
ERS年会壁报发布临床结果 迈威生物9MW1911价值几何？
中邮证券：给予迈威生物买入评级
证券之星 · 09-10
中邮证券：给予迈威生物买入评级
迈威生物-B（02493）披露9MW1911最新Ib/IIa期数据 将于2026年ERS大会以壁报形式发布
公告速递 · 09-04
迈威生物-B（02493）披露9MW1911最新Ib/IIa期数据 将于2026年ERS大会以壁报形式发布
迈威生物-B2026年中期营收3.12亿元，经调整净亏损5.24亿元
公告速递 · 09-04
迈威生物-B2026年中期营收3.12亿元，经调整净亏损5.24亿元
迈威生物：9MW1911将在2026年欧洲呼吸学会年会（ERS）以壁报形式报告最新临床数据
同花顺 · 09-04
迈威生物：9MW1911将在2026年欧洲呼吸学会年会（ERS）以壁报形式报告最新临床数据
迈威生物-B2026年8月股份变动月报表，股本维持不变
公告速递 · 09-04
迈威生物-B2026年8月股份变动月报表，股本维持不变
加载更多
公司概况
公司名称：
迈威生物-B
所属市场：
SEHK
上市日期：
--
主营业务：
公司是一家全产业链布局的创新型生物制药公司,始终秉承“让创新从梦想变成现实”的愿景,践行“探索生命,惠及健康”的使命,通过源头创新,为患者提供疗效更好、可及性更强的生物创新药,满足全球未被满足的临床需求。公司主营业务为研发、生产以及销售创新型药物和生物类似药。公司主要产品为抗体、ADC药物和重组蛋白、小分子化学药等药物。公司荣誉:上海产业人才队伍建设工作“优秀案例奖”、澳洲会计师公会“认可雇主”、星耀榜“2021中国生物创新药最具成长性年度大奖”、中国医药人才品牌榜总榜及最具竞争力品牌等。
发行价格：
--
{"stockData":{"symbol":"02493","market":"HK","secType":"STK","nameCN":"迈威生物-B","latestPrice":21.38,"timestamp":1790064491295,"preClose":21.2,"halted":0,"volume":216400,"delay":0,"changeRate":0.008490566037735837,"floatShares":47130200,"shares":447000000,"eps":-2.43,"marketStatus":"已收盘","change":0.18,"latestTime":"09-22 16:08:11","open":21.74,"high":21.88,"low":21.02,"amount":4651820,"amplitude":0.040566,"askPrice":21.38,"askSize":400,"bidPrice":21.3,"bidSize":1000,"shortable":0,"etf":0,"ttmEps":-2.422,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1790127000000},"marketStatusCode":5,"adr":0,"listingDate":1777305600000,"exchange":"SEHK","adjPreClose":21.2,"openAndCloseTimeList":[[1790040600000,1790049600000],[1790053200000,1790064000000]],"volumeRatio":1.017491,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"688062","market":"SH","secType":"STK","nameCN":"迈威生物-U","latestPrice":28.2,"timestamp":1790060400000,"preClose":28.06,"halted":0,"volume":9769400,"delay":0,"premium":"-35.26"}},"requestUrl":"/m/hq/s/02493","defaultTab":"news","newsList":[{"id":"2669159966","title":"9月21日迈威生物涨5.41%，中航优选领航混合发起A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2669159966","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669159966?lang=zh_cn&edition=full","pubTime":"2026-09-21 16:40","pubTimestamp":1789980017,"startTime":"0","endTime":"0","summary":"证券之星消息，9月21日迈威生物涨5.41%，收盘报28.06元，换手率4.31%，成交量9.93万手，成交额2.78亿元。根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共7家，其中持有数量最多的公募基金为中航基金的中航优选领航混合发起A。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092100020858.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","02493"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669159139","title":"迈威生物涨5.41%，中邮证券一周前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2669159139","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669159139?lang=zh_cn&edition=full","pubTime":"2026-09-21 16:39","pubTimestamp":1789979998,"startTime":"0","endTime":"0","summary":"今日迈威生物（688062）涨5.41%，收盘报28.06元。2026年9月10日，中邮证券研究员盛丽华发布了对迈威生物的研报《商业化提速，Nectin-4 ADC迈入价值兑现关键期》，该研报对迈威生物给出“买入”评级。证券之星数据中心根据近三年发布的研报数据计算，该研报作者对此股的盈利预测准确度为49.49%。证券之星数据中心计算显示，对该股盈利预测较准的分析师团队为中泰证券的祝嘉琦。迈威生物（688062）个股概况：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092100020849.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["161027","02493"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668861188","title":"迈威生物：基于上半年的增长，对今年的药品销售收入预期较为乐观","url":"https://stock-news.laohu8.com/highlight/detail?id=2668861188","media":"同花顺","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668861188?lang=zh_cn&edition=full","pubTime":"2026-09-20 13:22","pubTimestamp":1789881720,"startTime":"0","endTime":"0","summary":"近日，迈威生物-U(688062.SH)发布投资者关系活动记录表。其中提到，公司不对全年销售收入做具体数字的预期。但基于上半年的增长，对今年的药品销售收入预期较为乐观。迈威在成立之初就开始 ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun_highlight","url":"http://news.10jqka.com.cn/20260920/c680089763.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://news.10jqka.com.cn/20260920/c680089763.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun_highlight","symbols":["BK1161","02493"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668188865","title":"迈威生物：公司TCE平台的第一款分子LILRB4/CD3中美临床均已获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2668188865","media":"同花顺","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668188865?lang=zh_cn&edition=full","pubTime":"2026-09-20 13:19","pubTimestamp":1789881540,"startTime":"0","endTime":"0","summary":"近日，迈威生物-U(688062.SH)发布投资者关系活动记录表。其中提到，公司TCE技术平台采用创新的差异化设计策略，打造了自己的特色：1)自主开发的CD3抗体分子库。涵盖了从强效激活到温和激活 ...","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun_highlight","url":"http://news.10jqka.com.cn/20260920/c680089733.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://news.10jqka.com.cn/20260920/c680089733.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun_highlight","symbols":["02493","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668900706","title":"迈威生物：2MW7141去年完成了海外授权，目前处于临床前阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2668900706","media":"同花顺","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668900706?lang=zh_cn&edition=full","pubTime":"2026-09-20 13:16","pubTimestamp":1789881360,"startTime":"0","endTime":"0","summary":"近日，迈威生物-U(688062.SH)发布投资者关系活动记录表。其中提到，公司自主研发的小核酸平台，拥有包括修饰、递送技术等多项专利。公司双靶点小核酸药物协同调控效应明确，临床前研究中展 ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun_highlight","url":"http://news.10jqka.com.cn/20260920/c680089697.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://news.10jqka.com.cn/20260920/c680089697.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun_highlight","symbols":["02493","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668709900","title":"迈威生物：B7-H3 ADC的适应症主要面向鳞状非小细胞肺癌，下半年正式启动","url":"https://stock-news.laohu8.com/highlight/detail?id=2668709900","media":"同花顺","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668709900?lang=zh_cn&edition=full","pubTime":"2026-09-20 13:08","pubTimestamp":1789880880,"startTime":"0","endTime":"0","summary":"近日，迈威生物-U(688062.SH)发布投资者关系活动记录表。其中提到，公司B7-H3ADC的适应症主要面向鳞状非小细胞肺癌。公司已完成关于肺鳞癌单药III期临床试验的沟通交流，下半年正式启动，有 ...","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun_highlight","url":"http://news.10jqka.com.cn/20260920/c680089639.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://news.10jqka.com.cn/20260920/c680089639.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun_highlight","symbols":["BK1161","02493"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668900363","title":"迈威生物：ST2单抗目前开展的是COPD的IIb期临床，期中分析有望在今年年内完成","url":"https://stock-news.laohu8.com/highlight/detail?id=2668900363","media":"同花顺","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668900363?lang=zh_cn&edition=full","pubTime":"2026-09-20 12:03","pubTimestamp":1789876980,"startTime":"0","endTime":"0","summary":"近日，迈威生物-U(688062.SH)发布投资者关系活动记录表。其中提到，ST2单抗目前开展的是COPD的IIb期临床，期中分析有望在今年年内完成，并根据分析结果，沟通III期注册临床方案，届时会合规 ...","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun_highlight","url":"http://news.10jqka.com.cn/20260920/c680089038.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://news.10jqka.com.cn/20260920/c680089038.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun_highlight","symbols":["BK1161","02493"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668290086","title":"迈威生物：Nectin-4 ADC是公司目前有望最先获得商业化验证的原创新药","url":"https://stock-news.laohu8.com/highlight/detail?id=2668290086","media":"同花顺","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668290086?lang=zh_cn&edition=full","pubTime":"2026-09-20 11:54","pubTimestamp":1789876440,"startTime":"0","endTime":"0","summary":"近日，迈威生物-U(688062.SH)发布投资者关系活动记录表。其中提到，Nectin-4ADC是公司目前最为重要且有望最先获得商业化验证的原创新药。美国已经开展了针对拓扑异构酶ADC经治的TNBC的临床 ...","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun_highlight","url":"http://news.10jqka.com.cn/20260920/c680088956.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://news.10jqka.com.cn/20260920/c680088956.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun_highlight","symbols":["02493","BK1161","159992","MEDX","06978","BK1574","LNGR","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1114807153","title":"迈威生物-B(02493)三项议案高票获批 第四次临时股东会完成","url":"https://stock-news.laohu8.com/highlight/detail?id=1114807153","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1114807153?lang=zh_cn&edition=full","pubTime":"2026-09-17 22:32","pubTimestamp":1789655528,"startTime":"0","endTime":"0","summary":"2026年9月17日，迈威（上海）生物科技股份有限公司在上海召开2026年第四次临时股东大会。本次会议通过现场投票与网络投票相结合的方式进行。会议共有125名A股及H股股东及股东代表出席，合计代表表决权股份201,363,891股，占公司有表决权股份总数的45.1957%。其中，A股股东及代表124人，持股193,707,891股；H股股东及代表1人，持股7,656,000股。股东大会审议并分别以99.9099%、99.9099%及99.9051%的表决比例通过以下三项议案：。公告显示，本次股东大会无任何议案被否决。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02493"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1147752660","title":"迈威生物-B公布2026年第四次临时股东会表决结果及章程修订进展","url":"https://stock-news.laohu8.com/highlight/detail?id=1147752660","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1147752660?lang=zh_cn&edition=full","pubTime":"2026-09-17 22:15","pubTimestamp":1789654542,"startTime":"0","endTime":"0","summary":"迈威（上海）生物科技股份有限公司9月17日公告披露，其2026年第四次临时股东大会已于2026年9月17日举行，会议由董事长及执行董事刘大涛主持，全部董事均亲身或以电子方式参会。根据植德律师事务所出具的法律意见，本次会议的召集、召开及表决程序符合相关法律法规和公司章程，表决结果有效。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02493"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668496057","title":"迈威生物：2026年第四次临时股东会决议公告","url":"https://stock-news.laohu8.com/highlight/detail?id=2668496057","media":"同花顺","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668496057?lang=zh_cn&edition=full","pubTime":"2026-09-17 21:08","pubTimestamp":1789650480,"startTime":"0","endTime":"0","summary":" 证券日报网讯 9月17日，迈威生物发布公告称，公司于2026年9月17日召开2026年第四次临时股东会，审议通过《关于与思努赛签订许可协议暨关联交易的议案》等多项 ...","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun_highlight","url":"http://news.10jqka.com.cn/20260917/c680029550.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://news.10jqka.com.cn/20260917/c680029550.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun_highlight","symbols":["BK1161","02493"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667592906","title":"9月14日迈威生物涨7.19%，中航优选领航混合发起A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2667592906","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667592906?lang=zh_cn&edition=full","pubTime":"2026-09-14 16:36","pubTimestamp":1789374990,"startTime":"0","endTime":"0","summary":"证券之星消息，9月14日迈威生物涨7.19%创60日新低，收盘报25.79元，换手率3.65%，成交量8.39万手，成交额2.11亿元。根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共7家，其中持有数量最多的公募基金为中航基金的中航优选领航混合发起A。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091400021114.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["02493","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667659292","title":"迈威生物涨7.19%，中邮证券四日前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2667659292","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667659292?lang=zh_cn&edition=full","pubTime":"2026-09-14 16:36","pubTimestamp":1789374981,"startTime":"0","endTime":"0","summary":"今日迈威生物（688062）涨7.19%，收盘报25.79元。2026年9月10日，中邮证券研究员盛丽华发布了对迈威生物的研报《商业化提速，Nectin-4 ADC迈入价值兑现关键期》，该研报对迈威生物给出“买入”评级。证券之星数据中心根据近三年发布的研报数据计算，该研报作者对此股的盈利预测准确度为49.49%。证券之星数据中心计算显示，对该股盈利预测较准的分析师团队为中泰证券的祝嘉琦。迈威生物（688062）个股概况：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091400021112.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["161027","02493"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666547508","title":"9月11日迈威生物跌6.02%，中航优选领航混合发起A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2666547508","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666547508?lang=zh_cn&edition=full","pubTime":"2026-09-11 16:34","pubTimestamp":1789115665,"startTime":"0","endTime":"0","summary":"证券之星消息，9月11日迈威生物跌6.02%创60日新低，收盘报24.06元，换手率3.73%，成交量8.59万手，成交额2.09亿元。根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共7家，其中持有数量最多的公募基金为中航基金的中航优选领航混合发起A。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091100035600.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["02493","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666544936","title":"ERS年会壁报发布临床结果 迈威生物9MW1911价值几何？","url":"https://stock-news.laohu8.com/highlight/detail?id=2666544936","media":"新浪证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666544936?lang=zh_cn&edition=full","pubTime":"2026-09-11 15:34","pubTimestamp":1789112040,"startTime":"0","endTime":"0","summary":"近日，迈威生物在2026年欧洲呼吸学会年会以壁报形式报告公布9MW1911针对既往吸烟的中重度COPD患者的Ib/IIa期临床研究数据。国内方面，除迈威生物9MW1911外，正大天晴、康方生物等企业的同类产品处于早期临床阶段。折现系数方面，迈威生物作为已实现产品商业化、具备成熟推广能力的创新药企，但9MW1911仍处于II期临床阶段，研发风险高于后期管线，对应折现率取15%。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/observe/2026-09-11/doc-inirmvzx5383615.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["02493","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666056053","title":"中邮证券：给予迈威生物买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2666056053","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666056053?lang=zh_cn&edition=full","pubTime":"2026-09-10 19:01","pubTimestamp":1789038082,"startTime":"0","endTime":"0","summary":"中邮证券有限责任公司盛丽华近期对迈威生物进行研究并发布了研究报告《商业化提速，Nectin-4 ADC迈入价值兑现关键期》，给予迈威生物买入评级。收入高速增长主要来自药品销售和技术授权共同驱动，其中药品销售收入2.12亿元，同比增长110.07%；君迈康MAH于2025年7月由君实生物变更至迈威生物后，自2025Q4开始由公司开票销售，26H1贡献国内销售收入7537万元。最新盈利预测明细如下：该股最近90天内共有4家机构给出评级，买入评级3家，增持评级1家。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091000035842.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["161027","02493"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1173900334","title":"迈威生物-B（02493）披露9MW1911最新Ib/IIa期数据 将于2026年ERS大会以壁报形式发布","url":"https://stock-news.laohu8.com/highlight/detail?id=1173900334","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1173900334?lang=zh_cn&edition=full","pubTime":"2026-09-04 22:41","pubTimestamp":1788532881,"startTime":"0","endTime":"0","summary":"2026年9月5日至9月9日，迈威（上海）生物科技股份有限公司将在巴塞罗那举行的2026年欧洲呼吸学会年会上，以壁报形式公布其自主研发创新单克隆抗体9MW1911针对既往吸烟的中重度慢性阻塞性肺疾病患者Ib/IIa期临床研究最新结果。本次随机、双盲、安慰剂对照、多次给药、剂量递增研究共入组80例受试者，分别接受100 mg、300 mg、600 mg、900 mg剂量的9MW1911或安慰剂，每4周给药1次。安全性方面，研究显示9MW1911整体耐受性良好。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02493"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1191846223","title":"迈威生物-B2026年中期营收3.12亿元，经调整净亏损5.24亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=1191846223","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1191846223?lang=zh_cn&edition=full","pubTime":"2026-09-04 21:18","pubTimestamp":1788527882,"startTime":"0","endTime":"0","summary":"2026年上半年，迈威生物-B实现营收3.12亿元，同比增长209.1%。经调整净亏损5.24亿元，相比去年同期的5.52亿元下降约5.1%。当期毛利达2.36亿元，同比增长198.6%。经营活动所用现金净额为5.09亿元，上年同期为0.34亿元。财报显示，销售及分销开支为1.39亿元，同比增长36.4%；研发成本为4.31亿元，同比增长10.0%；行政开支为1.08亿元，同比下降9.0%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"迈威生物-B2026年中期营收3.12亿元，经调整净亏损5.24亿元","news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02493"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664336289","title":"迈威生物：9MW1911将在2026年欧洲呼吸学会年会（ERS）以壁报形式报告最新临床数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2664336289","media":"同花顺","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664336289?lang=zh_cn&edition=full","pubTime":"2026-09-04 18:52","pubTimestamp":1788519120,"startTime":"0","endTime":"0","summary":"人民财讯9月4日电，迈威生物(688062)9月4日公告，公司将在2026年9月5日—9月9日于巴塞罗那举行的2026年欧洲呼吸学会年会(ERS)中，以壁报形式公布9MW1911针对既往吸烟的中重度COPD患者的Ib/I ...","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun_highlight","url":"http://news.10jqka.com.cn/20260904/c679615433.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://news.10jqka.com.cn/20260904/c679615433.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun_highlight","symbols":["02493","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1186672462","title":"迈威生物-B2026年8月股份变动月报表，股本维持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1186672462","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1186672462?lang=zh_cn&edition=full","pubTime":"2026-09-04 16:42","pubTimestamp":1788511376,"startTime":"0","endTime":"0","summary":"迈威（上海）生物科技股份有限公司于2026年9月4日公布了截至2026年8月31日的股份变动月报表。报告显示，公司当月未发生新增发行、回购或注销等股份变动，股本结构保持稳定。根据公告，本期末公司法定注册股本总额为人民币446,730,200元。公司声明其已遵守香港联合交易所有限公司相关上市规则及当地法律法规的规定。本次公告由迈威生物-B联席公司秘书王鹤飞女士签署。公司表示，将继续严格履行披露义务，确保信息公开透明。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02493"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.mabwell.com","stockEarnings":[{"period":"1week","weight":0.0281},{"period":"1month","weight":-0.0337},{"period":"3month","weight":-0.1846},{"period":"6month","weight":-0.233},{"period":"ytd","weight":-0.233}],"compareEarnings":[{"period":"1week","weight":0.005},{"period":"1month","weight":-0.0372},{"period":"3month","weight":0.0731},{"period":"6month","weight":-0.0116},{"period":"1year","weight":-0.0566},{"period":"ytd","weight":-0.0229}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"公司是一家全产业链布局的创新型生物制药公司,始终秉承“让创新从梦想变成现实”的愿景,践行“探索生命,惠及健康”的使命,通过源头创新,为患者提供疗效更好、可及性更强的生物创新药,满足全球未被满足的临床需求。公司主营业务为研发、生产以及销售创新型药物和生物类似药。公司主要产品为抗体、ADC药物和重组蛋白、小分子化学药等药物。公司荣誉:上海产业人才队伍建设工作“优秀案例奖”、澳洲会计师公会“认可雇主”、星耀榜“2021中国生物创新药最具成长性年度大奖”、中国医药人才品牌榜总榜及最具竞争力品牌等。","exchange":"SEHK","name":"迈威生物-B","nameEN":"MABWELL-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"迈威生物-B(02493)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供迈威生物-B(02493)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"迈威生物-B,02493,迈威生物-B股票,迈威生物-B股票老虎,迈威生物-B股票老虎国际,迈威生物-B行情,迈威生物-B股票行情,迈威生物-B股价,迈威生物-B股市,迈威生物-B股票价格,迈威生物-B股票交易,迈威生物-B股票购买,迈威生物-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"迈威生物-B(02493)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供迈威生物-B(02493)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}